Dual optic accommodating IOL offers good quality of life

Article

Dual optic accommodating IOLs provide a more noticeable positive impact on a patient's quality of life than multifocal IOLs, according to Andrea Galvis and Ivan Ossma of the Instituto para Ninos Ciegos y Sordos, Columbia.

Dual optic accommodating IOLs provide a more noticeable positive impact on a patient's quality of life than multifocal IOLs, according to Andrea Galvis and Ivan Ossma of the Instituto para Ninos Ciegos y Sordos, Columbia.

They conducted a non-concurrent case series involving four patient groups implanted with multifocal IOLs or dual optic accommodating lenses: Alcon's Acrysof ReSTOR (n=27), AMO's ReZoom (n=28), AMO's Tecnis multifocal (n=34) and Visiogen's Synchrony dual optic accommodating IOL (n=31).

Subjects were matched based on age at time of implant and the absence of ocular co-morbidity. An adapted VF-7 questionnaire was completed by subjects three and six months after the second eye had received the implant and a questionnaire regarding halo and glare sensitivity was also mailed to all subjects.

The preoperative VF-7 scores ranged from 33.4 to 37.5 for all four groups. At six months follow-up, the mean VF-7 scores were 78.4 in the ReSTOR group, 81.7 in the Tecnis group, 71.5 in the ReZoom group and 84.2 in the Synchrony group. Halos occurred most often in the ReZoom group (21%) and least often in the Synchrony group (6.4%).

Glavis and Ossma concluded from their study that the dual optic accommodating IOL, Synchrony, not only offers patients a better quality of life, but it also yields a greater range of vision when compared to multifocal lenses.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.